argenex (NASDAQ:ARGX – Free Report) had its target price hoisted by Wells Fargo & Company from $1,355.00 to $1,356.00 in a research report report published on Wednesday morning,Benzinga reports. They currently have an overweight rating on the stock.
Other analysts have also recently issued research reports about the company. Wall Street Zen cut argenex from a “buy” rating to a “hold” rating in a research report on Saturday, September 19th. HC Wainwright boosted their price target on argenex from $940.00 to $1,202.00 and gave the stock a “buy” rating in a research report on Tuesday, August 18th. Morgan Stanley boosted their price target on argenex from $1,230.00 to $1,250.00 and gave the stock an “overweight” rating in a research report on Monday, August 31st. Piper Sandler upped their price objective on argenex from $1,075.00 to $1,215.00 and gave the stock an “overweight” rating in a research note on Monday, August 17th. Finally, DZ Bank reaffirmed a “buy” rating on shares of argenex in a research report on Friday, October 9th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,151.95.
View Our Latest Stock Report on argenex
argenex Stock Performance
Shares of argenex stock opened at $819.14 on Wednesday. The stock has a market cap of $51.25 billion, a price-to-earnings ratio of 31.46, a price-to-earnings-growth ratio of 0.78 and a beta of 0.44. The stock has a 50 day moving average price of $956.23 and a 200-day moving average price of $880.73. argenex has a one year low of $661.85 and a one year high of $1,072.75.
argenex (NASDAQ:ARGX – Get Free Report) last issued its quarterly earnings results on Tuesday, July 21st. The company reported $7.32 EPS for the quarter, beating the consensus estimate of $5.86 by $1.46. The company had revenue of $1.54 billion for the quarter, compared to the consensus estimate of $1.45 billion. argenex had a net margin of 32.19% and a return on equity of 43.59%. Sell-side analysts predict that argenex will post 28.71 earnings per share for the current fiscal year.
Institutional Investors Weigh In On argenex
A number of large investors have recently modified their holdings of ARGX. Whipplewood Advisors LLC purchased a new position in shares of argenex in the 1st quarter valued at approximately $28,000. Eastern Bank acquired a new stake in argenex in the 2nd quarter worth approximately $32,000. Axiom Investment Management LLC purchased a new stake in argenex during the 1st quarter worth approximately $50,000. WPG Advisers LLC grew its position in argenex by 17.8% during the 1st quarter. WPG Advisers LLC now owns 86 shares of the company’s stock worth $63,000 after purchasing an additional 13 shares during the last quarter. Finally, Mather Group LLC. grew its position in argenex by 19.1% during the 3rd quarter. Mather Group LLC. now owns 81 shares of the company’s stock worth $78,000 after purchasing an additional 13 shares during the last quarter. Hedge funds and other institutional investors own 60.32% of the company’s stock.
argenex Company Profile
argenx SE (NASDAQ:ARGX) is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company combines antibody engineering technologies with disease biology to discover medicines that target the underlying mechanisms of immune-mediated disorders.
argenx’s leading product is efgartigimod, marketed as Vyvgart and Vyvgart Hytrulo in the United States. The therapies are designed to reduce disease-causing immunoglobulin G (IgG) antibodies by targeting the neonatal Fc receptor (FcRn).
Further Reading
- Five stocks we like better than argenex
- Bank of America Stock Sell-Off Looks Like a Buying Opportunity
- AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff?
- GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking
- Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?
Receive News & Ratings for argenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenex and related companies with MarketBeat.com's FREE daily email newsletter.
